2024
Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia
Garcia C, Lyons K, Liu T, Iacobucci I, Novak A, Argabright A, Donnelly A, Grandvallet Contreras J, Geng H, Smith S, Zhou X, Müschen M, Dick J, Haines J, D'Alessandro A, Mullighan C, Phang T, Kohler M, Witkowski M. Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood 2024, 144: 1446-1446. DOI: 10.1182/blood-2024-201015.Peer-Reviewed Original ResearchB-cell acute lymphoblastic leukemiaB-ALL cell linesCAR-TCAR-T therapyB-ALL cellsAcute lymphoblastic leukemiaHuman B-ALL cell linesTP53-MUTLoss-of-function mutationsTP53 mutationsLymphoblastic leukemiaCD19-directed chimeric antigen receptor T cellsB-ALL diagnosisRelapsed B-ALLRelapsed B-cell acute lymphoblastic leukemiaRelapsed/refractory B-cell acute lymphoblastic leukemiaFree fatty acid transportB cell acute lymphoblastic leukemia cellsChimeric antigen receptor T cellsCD19 CAR-T therapyHigh-risk genetic featuresCAR-T cell therapyAssociated with chemotherapy resistanceResistant to conventional chemotherapyPediatric B-ALL patients
2023
Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors
Chen P, Raghunandan R, Müschen M, Katz S. Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors. Blood 2023, 142: 6805. DOI: 10.1182/blood-2023-186161.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaChimeric antigen receptor T cellsAntigen receptor T cellsLarge B-cell lymphomaReceptor T cellsT cellsLymphoma cell linesHGF/METMET expressionOCI-Ly3CD69 expressionDLBCL cell linesCD19-CARSolid tumorsCell linesAnti-Met monoclonal antibodiesCD19 CAR T cellsNegative diffuse large B-cell lymphomaRefractory B-cell malignanciesLoss of CD19B-cell depletionActivation marker CD69Classic Hodgkin lymphomaJurkat T cells
2018
Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors
Qin H, Dong Z, Wang X, Cheng W, Smith D, Song J, Aldoss I, Muschen M, Forman S, Kwak L. Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. Blood 2018, 132: 1411. DOI: 10.1182/blood-2018-99-117513.Peer-Reviewed Original ResearchCD19 CAR T cellsCAR T cellsCAR T-cell therapyT-cell therapyBAFF-R expressionT cellsB-cell malignanciesAntigen lossB-cell tumorsCell malignanciesClonal B-cell tumorChimeric antigen receptor T cellsAntigen receptor T cellsSame donorCD22 CAR T cellsSurface stainingCD19 antigen lossLoss of CD19Degranulation marker CD107aCells/mouseProgressive tumor growthIFN-γ productionReceptor T cellsSame healthy donorsPatient-derived xenografts